Akash Tewari
Stock Analyst at Jefferies
(2.04)
# 2,916
Out of 4,749 analysts
59
Total ratings
36.36%
Success rate
-2.58%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Upgrades: Buy | $63 → $70 | $58.95 | +18.74% | 3 | Dec 16, 2024 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $95 | $63.36 | +49.94% | 2 | Nov 15, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $96 → $150 | $123.77 | +21.19% | 3 | Sep 17, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Buy | $11 → $16 | $4.47 | +257.94% | 3 | Sep 10, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $177 → $189 | $151.82 | +24.49% | 2 | Aug 19, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $80 | $29.01 | +175.77% | 2 | Jul 31, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Buy | $29 → $75 | $31.90 | +135.11% | 1 | Jul 16, 2024 | |
| LLY Eli Lilly | Maintains: Buy | $994 → $1,015 | $811.08 | +25.14% | 6 | Jun 24, 2024 | |
| ALKS Alkermes | Maintains: Buy | $42 → $50 | $31.53 | +58.58% | 6 | Apr 9, 2024 | |
| APGE Apogee Therapeutics | Maintains: Buy | $37 → $75 | $41.36 | +81.33% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $22.99 | +34.84% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $32 → $40 | $17.61 | +127.14% | 2 | Dec 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $935 → $937 | $672.98 | +39.23% | 4 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $12 | $1.97 | +509.14% | 2 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $26.52 | +47.06% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $5.11 | +252.25% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $655.13 | -21.69% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.46 | +303.59% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $98.82 | +26.49% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $14.60 | -24.66% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $30 → $3.6 | $5.26 | -31.56% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $6.07 | +180.07% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $49.46 | +51.64% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $334.80 | -54.90% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $33.15 | -15.54% | 3 | Oct 7, 2021 |
Bristol-Myers Squibb Company
Dec 16, 2024
Upgrades: Buy
Price Target: $63 → $70
Current: $58.95
Upside: +18.74%
BioMarin Pharmaceutical
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $63.36
Upside: +49.94%
BioNTech SE
Sep 17, 2024
Upgrades: Buy
Price Target: $96 → $150
Current: $123.77
Upside: +21.19%
Relay Therapeutics
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $4.47
Upside: +257.94%
Neurocrine Biosciences
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $151.82
Upside: +24.49%
Apellis Pharmaceuticals
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $29.01
Upside: +175.77%
Ionis Pharmaceuticals
Jul 16, 2024
Upgrades: Buy
Price Target: $29 → $75
Current: $31.90
Upside: +135.11%
Eli Lilly
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $811.08
Upside: +25.14%
Alkermes
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $31.53
Upside: +58.58%
Apogee Therapeutics
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $41.36
Upside: +81.33%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $22.99
Upside: +34.84%
Dec 6, 2023
Upgrades: Buy
Price Target: $32 → $40
Current: $17.61
Upside: +127.14%
Nov 28, 2023
Maintains: Buy
Price Target: $935 → $937
Current: $672.98
Upside: +39.23%
Nov 28, 2023
Maintains: Buy
Price Target: $15 → $12
Current: $1.97
Upside: +509.14%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $26.52
Upside: +47.06%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $5.11
Upside: +252.25%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $655.13
Upside: -21.69%
Jun 7, 2023
Initiates: Buy
Price Target: $18
Current: $4.46
Upside: +303.59%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $98.82
Upside: +26.49%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $14.60
Upside: -24.66%
Dec 16, 2022
Downgrades: Hold
Price Target: $30 → $3.6
Current: $5.26
Upside: -31.56%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $6.07
Upside: +180.07%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $49.46
Upside: +51.64%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $334.80
Upside: -54.90%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $33.15
Upside: -15.54%